Étiquette : Oncology

QIMA LIFE SCIENCES

by jbertholdin Institutions, Service Providers & others

QIMA LIFE SCIENCES

About the company

QIMA Life Sciences brings together QIMA Bioalternatives, Newtone Technologies, and Monasterium Laboratory. The companies provide innovative testing and research solutions ranging from in silico screening to clinical imaging, as well as in vitro and ex vivo assays and non-invasive clinical sample bioanalysis. They also offer the exclusive “Blood assay solutions” for fresh whole blood testing.

They contribute to the development of testing methods as an alternative to animal experimentation, by offering solutions dedicated to preclinical research and to the development of drug candidates and to cosmetic active ingredients and formulations.

About the solution

The company provides a 360° offer with innovative testing and research solutions ranging from in silico screening to clinical imaging, as well as in vitro and ex vivo assays and non-invasive clinical sample bioanalysis.

Website
Key information

–  Therapeutic areas: Dermatology, Oncology, immunology, Neurobiology

–  Based in: Gençay (FRANCE)

–  Employees: 51 – 200

– Created in: 1996

NETRIS PHARMA

by jbertholdin Biotech, Pharma

NETRIS PHARMA

About the company

Netris Pharma is a clinical-stage company developing innovative therapeutics to improve treatment outcome for cancer patients, targeting resistance to both chemotherapy and immunotherapy.

About the solution

Their lead asset, NP137, is a first-in-class anti-Netrin1 monoclonal antibody currently investigated in a randomized phase II in Endometrial and Cervical cancers as well as in 5 exploratory trials.

Website
Key information

–  Therapeutic areas: Oncology and Women Health

–  Based in: Lyon (FRANCE)

–  Employees: 11 – 50

– Created in: 2008

ROSETTA OMICS

by jbertholdin Biotech, Medtech, Pharma

ROSETTA OMICS

About the company

Rosetta Omics pioneers precision medicine through tumor characterization using spatial multiomics, deep mass spectrometry and AI. Their focus is to optimize first-line treatments by matching therapies with patients effectively, starting with liver and colon cancers. They aim to empower oncologists with a transformative tool, enhancing patient care, and cutting costs. Collaborating with pharma and biotech firms, they seek to identify new biomarkers, accelerating therapeutic and diagnostic innovations.

Committed to scientific advancement and patient well-being, Rosetta Omics is reshaping cancer care. Through cutting-edge technologies and comprehensive multiomics analysis, they provide personalized treatment insights for improved outcomes. Rosetta Omics is at the forefront of precision medicine, driven by innovation, collaboration, and a commitment to saving lives.

About the solution

Their biopsy-based predictive test can be integrated within the standard clinical procedure of biopsy collection for diagnostics to assist in the decision-making process. Their services and products can also identify biomarkers of clinical interest and be used to discover new targets for drug development.

Website
Key information

–  Therapeutic areas: Oncology, Cancer, Liver cancer, Colon cancer, Precision medicine, AI

–  Based in: Paris (FRANCE)

–  Employees: 1 – 10

– Created in: 2023

ATLANTIC BONE SCREEN

by jbertholdin Biotech, Pharma

ATLANTIC BONE SCREEN

About the company

Atlantic Bone Screen is a French CRO providing non-GLP preclinical services.
Atlantic Bone Screen has a strong know-how in the field of osteoarticular indications / bone and joint diseases / biomaterials : inflammation & oncology & dermatology.
Atlantic Bone Screen has developed in vitro tests, in vivo animal models and benefits from robust and state-of-the-art platforms for 2D and 3D imaging, histology and histopathology.
Atlantic Bone Screen supports biotech and pharma companies to identify and characterize the therapeutic potential of their drug candidates, nutraceuticals and biomaterials through validated models and customized preclinical studies.

About the solution

Their specific expertise in bone physiology and bone diseases, cartilage and inflammatory diseases, and cancer models sets them apart from other global CROs.

Based on their internal experts and scientific network, they address their customers’ questions regarding their candidates and support them in screening, characterization, and validation of their leads to generate strong data for advancing through regulatory stages.

Additionally, their flexibility in customizing study designs, readouts, and communication and providing comprehensive reports throughout projects is highlighted as a real strength by their partners (96% of customers were either satisfied or very satisfied in the 2023 satisfaction survey).

Website
Key information

–  Therapeutic areas: Oncology, Bone Diseases, Osteoarticular Diseases, Inflammation, Dermatology, Cosmetics, Biomaterials.

–  Based in: Nantes

–  Employees: 11 – 50

– Created in: 2005

PEP-THERAPY

by jbertholdin Biotech, Pharma

PEP-THERAPY

About the company

Originally spun out from the prestigious Institut Curie and Sorbonne University (Paris, France), PEP-Therapy is a clinical-stage company developing first-in-class peptides as targeted therapies for the treatment of aggressive cancers.

Following promising Phase Ia results, including preliminary signs of efficacy, PEP-Therapy is now performing Phase Ib trials (NCT 04733027) in both Platinum-Resistant Ovarian Cancer and Pancreatic Ductal Adenocarcinoma (PROC and PDAC).

PEP-Therapy is strongly backed by international investors: Seventure Partners, i&i Prague, Italian Angels for Growth (IAG), Doorway, Anaxago, Magna Capital Partners (MCP), BAdGE, and Majoie family.

About the solution

PEP-010, PEP-Therapy’s flagship product, in summary:
– First-in-class bifunctional targeted peptide
– MoA: triggering apoptosis by disruption of Caspase-9/PP2A interaction
– Phase Ia promising results: – Favorable safety and tolerability profiles, RP2D determined in monotherapy and in combination with paclitaxel – Promising signals of antitumor activity
– Phase Ib trials underway (NCT 04733027): multicenter (in partnership with leading clinical oncology centers: Institut Curie, Gustave Roussy)
– Focus on PROC and PDAC (Platinum-Resistant Ovarian Cancer and Pancreatic Ductal Adenocarcinoma) in combination with paclitaxel and gemcitabine
– Indication expansion potential, in solid and in liquid cancers
– Translational biomarkers development ongoing
– Spin-off from the prestigious Institut Curie and Sorbonne University. Backed by international investors.

Website
Key information

–  Therapeutic areas: Oncology, Cancer

–  Based in: Paris (FRANCE)

–  Employees: 1 – 10

– Created in: 2014

BDC

by jbertholdin Institutions, Service Providers & others

BIOTECH DEVELOPPEMENT CONSEILS

About the company

BDC is a global life sciences consulting firm that works with innovative medium-size companies to aggressively drive growth and capture extraordinary opportunities.
BDC helps to create value through technology-driven & long-term partnerships with industrial and pharma companies thanks to its extensive and powerful network. BDC benefits from the trust from industry higher management and from multiple proven competences in defining and applying strategies.

The management of BDC is composed of former executives from the industrial health sector and thanks to their expertise, BDC can assist start-ups and biotechs in almost every aspects of their “bio-business”: global strategy, business development (strategic alliances, portfolio management, licensing-in/out, distribution deals, …), discovery, R&D, legal aspects (contracts, intellectual property, litigation, …), to name a few.
Thanks to its team BDC can conduct business internationally and has offices in France, Israel, Switzerland, Singapore and Germany.

About the solution

BDC is specialized in corporate strategy, business development, assets valorization, technology transfer, fundraising, …

Website
Key information

–  Therapeutic areas: Oncology, Inflammation, CGT, AI, CNS, Metabolic diseases, Dermatology, Medical Devices, Diagnostics

–  Based in: Paris (FRANCE)

–  Employees: 1 – 10

– Created in: 2002

OWKIN

by jbertholdin Biotech, Pharma

OWKIN

About the company

By understanding complex biology through artificial intelligence, they integrate the best of human and AI capabilities to develop improved drugs and diagnostics at scale.

Through their understanding of complex biology using AI, they identify new treatments, de-risk and accelerate clinical trials, and develop diagnostic tools to reduce time to impact for patients.

Owkin was founded with this vision in mind, combining human expertise with cutting-edge technology to revolutionize the medical field.

About the solution

Owkin works with top academic centers to curate, enrich, and generate deep, multimodal data that is AI-ready.

They apply AI to multimodal, KOL-curated data to subtype patients and identify novel biomarkers to inform drug discovery, de-risk clinical trials, and develop and deploy diagnostics in clinical practice.

Their drug discovery engines leverage their expertise in AI, biology, and medicine to understand the intricate biological interactions that define specific patient subgroups. Through their AI engines, they deliver novel drug targets and optimize drug positioning.

They combine machine learning methodologies, patient data, and innovative modalities to increase the probability of success of clinical trials.

Their AI diagnostics help pre-screen for biomarkers and predict outcomes — giving healthcare providers a fuller picture of a patient’s disease. This means more patients can benefit from targeted therapies.

Website
Key information

–  Therapeutic areas: Oncology, Immunology and Inflammation, Cardiovascular

–  Based in: Based in Paris (FRANCE)
Offices in New York City (USA) and in London (UK)

–  Employees: 201 – 500

– Created in: 2016

STROMACARE

by jbertholdin Biotech, Pharma

STROMACARE

About the company


StromaCare is a biotech company specialized in discovering and developing new cancer treatments through their understanding of stromal tissue biology. They develop innovative oncology drugs, both as standalone treatments and in combination with other therapies, for treating solid tumors based on the novel approach of modulating stromal components. How cancer develops and progresses is linked to the tumor stroma. The stroma limits the efficiency of immune cells against tumor cells, facilitates the migration of tumor cells, and prevents the access of treatments to the tumor.

At StromaCare, they aim to make the stroma ‘permeable’ to immune cells and other molecules of interest to eliminate the tumor.

About the solution

StromaCare identified a set of stromal players and characterized their roles. Their lead drug candidate, STRO-501, a monoclonal antibody, targets a key stromal player called βig-h3, which is common to most cancers and serves as a novel T-cell regulator. This lead monoclonal antibody has demonstrated strong efficacy in preclinical studies, shows a favorable safety profile, and has received a favorable opinion from the EMA. StromaCare aims to start their clinical trial in 18 to 24 months, either as a standalone treatment or in combination with anti-PD1 in resistant cancers.

Their pipeline includes other targets and antibodies addressing different aspects of stromal biology.

Website
Key information

–  Therapeutic areas: Oncology, Immune diseases

–  Based in: Lyon (FRANCE)

–  Employees: 11 – 50

– Created in: 2022

STEP PHARMA

by jbertholdin Biotech, Pharma

STEP PHARMA

About the company

Step Pharma is the world leader in the discovery and development of inhibitors of CTPS1 (cytidine triphosphate synthase 1) for the treatment of cancer and autoimmune diseases. The company was founded in France in 2014 based upon the observation that genetic loss of CTPS1 led to a highly specific lymphocyte phenotype.

Step Pharma’s lead program STP938 is a potent, selective, oral inhibitor of CTPS1 currently in clinical development for the treatment of relapsed and refractory T-cell and B-cell lymphoma. Sensitivity to CTPS1 in solid tumors is conferred via a synthetic lethal approach driven by genomic loss of the paralog enzyme CTPS2. The prevalence of loss is >15% in multiple tumor types with highest prevalence (20%) in ovarian cancer. A Phase I/II study using biomarker selection in ovarian cancer patients will start in 3Q24.
They expect to deliver Proof of Concept data in both lymphoma and solid tumours in 2025.

About the solution

CTPS1 inhibition is a novel mechanism and STP938 is a First In Class molecule. There is a significant unmet need in T cell lymphoma with very few options after relapse from chemotherapy. STP938 has the potential to transform the treatment of both Peripheral and Cutaneous T cell lymphoma as well as provide options for patients with B cell lymphoma.

The ability to biomarker select solid tumor patients sensitive to STP938 opens up an opportunity to treat many solid tumor types with high unmet need including platinum refractory ovarian cancer. Our expectation is that success in one cancer type would enable progression to a tumor agnostic biomarker approval and ability to treat many tumor types including bladder, lung, pancreatic and gastric where prevalence of CTPS2 loss is high.

Website
Key information

–  Therapeutic areas: Oncology, Haematology

–  Based in: Saint-Genis-Puilly and Paris (FRANCE)
Cambridge (UK), Buchillon (SWITZERLAND)

–  Employees: 1 – 10

– Created in: 2014

CONTACT
Andrew ParkerChief Executive Officer

ap@step-ph.com

SATT CONECTUS

by jbertholdin Institutions, Service Providers & others

SATT CONECTUS

About the company

The SATT Network brings together 13 Technology Transfer Acceleration Companies in France. Conectus is the SATT for Alsace territory, based in Strasbourg and representing 2 Universities, INSERM and CNRS laboratories and engineering schools.
Committed to economic dynamism thanks to the scientific innovations resulting from public research, SATTs provide companies with high-potential technological solutions to improve their competitiveness.

Their main activity is to protect and invest in the development of technologies at early stages on the basis of academic discoveries. They propose technologies for out-licensing to existing companies, or to support start-up company creation.

With more than 650 startups created, the SATTs are the leading local players in the French government’s DeepTech Plan. They are connected to more than 150,000 researchers and offer privileged access to innovations from public laboratories. With their national network, they are the strategic partners of companies seeking growth through innovation.

About the solution

They offer several technologies for licensing or co-development: therapeutic assets in different therapeutic areas, drug discovery tools, formulation technologies, diagnostic technologies, etc… Our investment fund allows us to propose technologies more advanced than usual academic discoveries, with strong IP.

Website
Key information

–  Therapeutic areas: All therapeutic areas. Current programs in Oncology, CNS, Muscle diseases, Thrombosis, Inflammation…

–  Based in: Strasbourg

–  Employees: 11 – 50

– Created in: 2012